This multicenter study evaluates nelitolimod's effect on treatment-naïve advanced melanoma, suggesting its potential in combination with pembrolizumab.
Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.
No takes yet. Share an insight, caveat, or question.
Ribas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: